Month: May 2026

Commercial Vehicle Group (CVGI) – Post Call Commentary

Posted on by [email protected]


Thursday, May 07, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Growth Avenue. In Electrical Systems, CVG continues to pursue a differentiated solutions strategy, positioning the Company to increase content per vehicle. For example, due to the redundant nature from a safety perspective, the electrical content in an autonomous vehicle is almost double that of an ICE vehicle. This provides CVG with a significant growth opportunity, in our opinion. Similarly, in CVG’s legacy markets, as vehicles develop more content for either autonomous operation or feature comfort additions, that increases the content per vehicle.

End Markets. CVG’s key end markets, Electrical Systems and the Class 8 truck market, are showing signs of improvement. Management continues to expect the Electrical Systems market to expand by more than 10% in 2026. The Class 8 truck market is projected to grow by 9% in 2026, with recent orders suggesting the possibility of even greater growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Italian Pharma Giant Angelini Pays $4.1 Billion for Coral Gables-Based Catalyst Pharmaceuticals — and Gets a U.S. Beachhead in the Process

Posted on by [email protected]

Catalyst Pharmaceuticals (Nasdaq: CPRX), the Coral Gables-based rare disease biopharmaceutical company, is being acquired by Rome-headquartered Angelini Pharma in an all-cash deal valued at approximately $4.1 billion — or $31.50 per share. The transaction, unanimously approved by both boards, marks one of the largest biopharma acquisitions of a U.S.-listed rare disease company so far in 2026, and it carries particular significance for Angelini: it’s the Italian pharma group’s formal entry into the U.S. market after more than a century of operations centered in Europe.

The deal price represents a 21% premium to Catalyst’s unaffected closing share price on April 22 — the last trading day before deal speculation began leaking into the market — and a 28% premium to the 30-day volume-weighted average price through that same date. Blackstone funds are participating in the transaction alongside select international partners, with BNP Paribas acting as sole global coordinator and underwriter of the financing package. The acquisition is not subject to a financing condition, and closing is expected in the third quarter of 2026.

For Angelini, the strategic logic is hard to argue with. Catalyst has spent over two decades quietly building one of the more defensible portfolios in rare neurology. Its flagship product, FIRDAPSE® (amifampridine), remains the only FDA-approved, evidence-based treatment for Lambert-Eaton myasthenic syndrome — a rare and debilitating autoimmune disorder — in patients aged six and up. Its second major asset, AGAMREE® (vamorolone), received FDA approval in 2023 as a novel corticosteroid for Duchenne Muscular Dystrophy in patients as young as two. Rounding out the portfolio is FYCOMPA® (perampanel), an antiepileptic drug for partial-onset and generalized tonic-clonic seizures, the U.S. rights to which Catalyst acquired from Eisai in 2023.

That portfolio — three FDA-approved products, all in neurological rare disease, all with established commercial infrastructure — is precisely what Angelini has been building toward. The company has spent the last five years pivoting its global strategy around central nervous system disorders and brain health, including a partnership with Blackstone Life Sciences in GRIN Therapeutics. Acquiring Catalyst doesn’t just add products; it adds a fully operational U.S. commercial engine that would take years and considerable capital to replicate organically.

There’s one additional wrinkle worth noting. Separately from the acquisition announcement, Catalyst disclosed it has resolved pending patent litigation with Hetero USA over a generic FIRDAPSE challenge. The settlement — terms of which are confidential and subject to FTC and DOJ review as required by law — eliminates a key IP overhang that had lingered over the company’s most critical revenue-generating asset. The timing of that resolution, announced alongside a $4.1 billion buyout, is not coincidental. Clean IP, commercial scale, and a motivated foreign buyer: Catalyst’s management team played this about as well as a rare disease company could.

For CPRX shareholders, the deal delivers immediate, certain cash value at a meaningful premium after the stock had already performed well relative to the broader small-cap biotech landscape. Once the deal closes, Catalyst will operate as a wholly owned subsidiary of Angelini Pharma and delist from Nasdaq.

J.P. Morgan advised Catalyst. Centerview Partners, BNP Paribas, and Morgan Stanley co-advised Angelini Pharma.

Why a U.S.-Iran Peace Deal Could Unleash the Small-Cap Rally Nobody Is Talking About

Posted on by [email protected]

Markets surged Wednesday on a report that the U.S. and Iran may be closing in on an agreement to end a conflict that has strangled global energy markets for more than two months — and for small and microcap investors, the implications of a resolution go far deeper than the headline oil price move.

Axios reported Wednesday morning that the White House believes it is nearing a one-page memorandum of understanding with Iran designed to end the war and establish a framework for nuclear negotiations. WTI crude oil plunged as much as 15% intraday, touching $88 per barrel, while Brent crude dropped roughly 11%. The Russell 2000 responded with a 1.75% gain — outpacing the S&P 500’s 1.10% advance — as investors rotated into smaller, domestically-focused companies that have been disproportionately squeezed by the energy price shock.

The optimism, however, came with caveats. President Trump later told the New York Post it was “too soon” to prepare for a peace signing, and Iran had not formally confirmed a deal was close. As of late Wednesday, oil prices had partially recovered off their lows.

Still, the market reaction signals just how much weight the Strait of Hormuz crisis has carried on the broader economy — and on smaller companies specifically.

Since the U.S. and Israel launched strikes on Iran on February 28, triggering Iran’s closure of the Strait of Hormuz on March 4, the disruption has been characterized by the International Energy Agency as the largest supply disruption in the history of the global oil market. Roughly 27% of the world’s seaborne crude oil and petroleum products typically transit the strait. With that corridor effectively shut down, Brent crude surged past $120 per barrel at its peak, and national average gas prices climbed to $4.54 per gallon — a 50% increase since the war began.

For large-cap companies, elevated energy costs are painful but often manageable through hedging programs, pricing power, and diversified supply chains. For small and microcap companies, the math is different. Smaller firms tend to carry more floating-rate debt, operate on tighter margins, and have limited ability to pass cost increases through to customers. Transportation-dependent businesses — regional distributors, light manufacturers, construction firms, specialty retailers — have faced a compounding squeeze of higher fuel surcharges, rising input costs, and a Federal Reserve that has had to pause rate-cutting plans as inflation reaccelerates.

That last point matters enormously. The Fed’s rate trajectory was a central driver of the small-cap thesis heading into 2026. With the federal funds rate in the 3.50%–3.75% range following cuts throughout 2025, smaller companies carrying variable-rate debt were beginning to see meaningful margin relief. The Iran conflict put that tailwind at risk. An oil price normalization — even partial — reopens the path toward lower borrowing costs and takes significant pressure off balance sheets across the small-cap universe.

The deal, if it materializes, would not immediately normalize supply. Exxon CEO Darren Woods warned last week that even after the Strait reopens, tankers need to be repositioned, supply backlogs worked through, and strategic reserves refilled — a process he estimated could take months. Energy analysts have set $80–$90 per barrel as a likely new floor even in a resolution scenario.

But for small-cap investors, the direction matters as much as the destination. A credible de-escalation removes the tail risk of oil at $150 or $200 per barrel — scenarios that analysts had begun modeling — and restores a more predictable operating environment for the companies that ChannelChek covers.

The Russell 2000’s outperformance on Wednesday was not accidental. It was a preview of what a sustained resolution could mean for the segment of the market that has the most to gain.

Release – Sky Harbour to Report Its First Quarter 2026 Financial Results and Host Webcast Investor Call on May 14th, 2026

Posted on by [email protected]
Sky Harbour Logo

Research News and Market Data on SKYH

05/06/2026

WEST HARRISON, N.Y.–(BUSINESS WIRE)– Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, today announced that it will release its First Quarter 2026 financial results and file its quarterly report on Form 10-Q with the SEC after market close on Thursday, May 14th, 2026, and that it will host an investor webcast at 5:00 pm ET the same day. On the call, Sky Harbour will review quarterly financial results and provide a general business update. A question-and-answer session with Sky Harbour leadership will follow. Both the call and webcast are open to the general public.

The webcast will be publicly available in the UPCOMING EVENTS section of the Company’s investor relations website, https://ir.skyharbour.group. A replay of the webcast will be available on the Company’s website following the event.

To join the webcast, please use the following link:

https://events.q4inc.com/attendee/103067347

For the audio-only conference call, please use the following participant details:

USA – Toll-Free: (800) 715-9871
USA / International Toll: +1 (646) 307-1963
Conference ID: 2025177

If you have any questions or are interested in connecting with Sky Harbour leadership, please contact Investor Relations at [email protected].

About Sky Harbour Group Corporation

Sky Harbour Group Corporation is an aviation infrastructure company developing the first nationwide network of Home-Basing campuses for business aircraft. The Company develops, leases and manages general aviation hangars across the United States. Sky Harbour’s Home-Basing offering aims to provide private and corporate customers with the best physical infrastructure in business aviation, coupled with dedicated service tailored to based aircraft, offering the shortest time to wheels-up in business aviation. To learn more, visit www.skyharbour.group.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements about the expectations regarding future operations at Sky Harbour Corporation and its subsidiaries. When used in this press release, the words “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements are based on the current expectations of the management of Sky Harbour Group Corporation (the “Company”) as applicable and are inherently subject to uncertainties and changes in circumstances. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. For more information about risks facing the Company, see the Company’s annual report on Form 10-K for the year ended December 31, 2025, and other filings the Company makes with the SEC from time to time. The Company’s statements herein speak only as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SKYH Investor Relations:
[email protected]
Attn: Francisco X. Gonzalez, CFO

Source: Sky Harbour Group Corporation

Release – Star Equity Holdings Announces Proposal to Acquire GEE Group for $0.30 per Share

Posted on by [email protected]
Primary Logo

Research News and Market Data on STRR

May 6, 2026

Download PDF

Stock-For-Stock Transaction Using Star’s Publicly Listed Preferred Stock (Nasdaq: STRRP)

Management Needs to Agree to Normal Severance

OLD GREENWICH, Conn., May 06, 2026 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or “we”), a diversified holding company and a 5.4% stockholder of GEE Group, Inc. (NYSE American: JOB) (“GEE Group” or the “Company”), announced today that it has presented GEE Group’s Board of Directors (the “Board”) with an indication of interest for the potential acquisition of the Company. The indication of interest contemplates a stock-for-stock transaction whereby Star would acquire 100% of the outstanding shares of the Company’s common stock for $0.30 per share, using Star’s publicly listed 10% Series A Cumulative Perpetual Preferred Stock (Nasdaq: STRRP), valued based on its liquidation preference of $10.00 per share.

Jeff Eberwein, CEO of Star, commented, “GEE Group’s shareholders have been long‑suffering under a ‘go it alone’ strategy that has produced steep revenue declines, persistent losses, and a stock price that has declined 95% over the last 10 years. We believe becoming part of a larger platform like Star is the best way to maximize value for all JOB shareholders by eliminating public company costs and substantially reducing corporate overhead. With our experience investing in and overseeing professional services businesses, we are confident that this potential transaction can create meaningful, long‑term value for both JOB and STRR stockholders.”

About Star Equity Holdings, Inc.
Star Equity Holdings, Inc. is a diversified holding company that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities. Its current structure comprises four divisions: Building Solutions, Business Services, Energy Services, and Investments. For more information visit www.starequity.com.

Building Solutions
The Building Solutions division operates in three specialties: (i) modular building manufacturing; (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations; and (iii) glue-laminated timber (glulam) column, beam, and truss manufacturing.

Business Services
The Business Services division provides flexible and scalable recruitment solutions to a global clientele, servicing organizations at all levels, from entry-level positions to the C-suite. The division focuses on mid-market and enterprise organizations worldwide, partnering consultatively with talent acquisition, HR, and procurement leaders to build diverse, high-impact teams and drive business success.

Energy Services
The Energy Services division engages in the rental, sale, and repair of downhole tools used in the oil and gas, geothermal, mining, and water-well industries.

Investments
The Investments division manages and finances the Company’s real estate assets as well as its investment positions in private and public companies.

For more information contact: 
Star Equity Holdings, Inc.The Equity Group
Jeffrey E. EberweinLena Cati
CEOSenior Vice President
203-489-9501212-836-9611
[email protected][email protected]
  

May 6, 2026

GEE Group Inc.
Attn: Board of Directors
7751 Belfort Parkway, Suite 150
Jacksonville, Florida 32256

Dear Board of Directors,

Star Equity Holdings, Inc. (“Star”, “We”, “Our”) is pleased to present this preliminary, non-binding indication of interest (“IOI”) regarding the opportunity to explore a potential combination of Star and GEE Group Inc. (“GEE Group”, “JOB”, or the “Company”). Through our Investments division, we currently own approximately 5.4% of JOB’s outstanding common shares. We have performed due diligence solely using publicly available information and believe Star would be an excellent merger partner for the Company based on our preliminary analysis. We also believe this combination would reduce public company and corporate overhead costs on a combined basis and create value for the shareholders of both STRR and JOB.

Star is a publicly traded (NASDAQ: STRR), diversified holding company and has been operating in this capacity since September 2019. Star currently has four divisions: Building Solutions, Business Services, Energy Services, and Investments, and our acquisition strategy involves seeking both attractive bolt-on opportunities for our existing businesses as well as potentially entering entirely new segments where we believe we can create significant value.

We believe there are several compelling reasons why Star would be an excellent merger partner for GEE Group and its shareholders including:

  • Significant opportunities for public company overhead reduction by combining the two companies;
  • Increased focus from the operating management team on growing their staffing businesses with fewer public-company-related distractions; and,
  • Significant opportunities for collaboration with the seasoned business leaders at Star’s Hudson Talent Solutions business and Star’s other portfolio companies.

1. Purchase Price: Subject to the terms and conditions set forth herein, Star is prepared to purchase 100% of the Company’s outstanding common shares for $0.30 per share (the “Purchase Price”). The Purchase Price is based on our review of publicly available information and our familiarity with the industry dynamics impacting the Company. The Purchase Price represents an approximate 33% premium over the Company’s 4/30/2026 closing stock price of $0.2254 and an approximate 40% premium above the Company’s 1/21/26 stock price of $0.2149, the day before Star’s initial press release indicating its acquisition interest in JOB. The transaction will be structured as a stock-for-stock transaction. The Purchase Price shall be paid in shares of publicly listed Star Equity Holdings, Inc. 10% Series A Cumulative Perpetual Preferred Stock (Nasdaq: STRRP), the value of which is based on a liquidation preference of $10.00 per share. See Exhibit A for more information about STRRP.

Accordingly, the STRRP to JOB exchange ratio shall be 0.03 to 1.00, meaning Star will pay JOB shareholders 0.03 shares of STRRP for each share of JOB owned. Given that each share of STRRP receives $1.00 per year of cash dividends ($0.25 paid quarterly), this effectively means JOB shareholders, after the Transaction closes, will receive cash dividends equating to an approximate 13% dividend yield based on JOB’s current stock price.

2. Structure and Financing: The Transaction is currently contemplated as a stock purchase. We expect to fund the Transaction with preferred equity securities.

3. Employees / Management: We do not anticipate unilateral changes in the Company’s operations post-closing. However, we expect CEO Derek Dewan, CFO Kim Thorpe, and COO Alex Stuckey to forego the severance payments and benefits triggered by a change in control (“CIC”) within their employment agreements executed in April 2023. In lieu of these severance payments, we expect to enter into a settlement agreement with the aforementioned executives whereby each executive would receive the sum of (i) their “Base Salary” and (ii) their “Target Cash Bonus” for one year, payable in STRRP within 30 days of closing based on STRRP’s liquidation preference of $10.00 per share so that GEE Group’s management receives the same form of consideration as its shareholders.

4. Approvals: At the appropriate time, Star will seek Board approval to consummate the transaction, subject to satisfactory completion of due diligence, negotiation, and execution of the definitive agreement and related documents, and the satisfaction of customary conditions, and representations set forth in the definitive agreement.

5. Due Diligence: Star anticipates conducting standard due diligence comprised of a review of financial, operating, and legal information, as well as discussions with members of the Company’s management team, customers, and significant third-party vendors. In this regard, we expect you to provide us assistance as is reasonably requested and give access at reasonable times to all things related to the business and assets of the Company.

We are enthusiastic about proceeding and suggest we put an NDA in place, excluding the unnecessary standstill provision, as the next logical step in our discussions. If you have any questions about anything contained herein or our proposal, please contact me at (203) 489-9501. We look forward to hearing from you.

Sincerely,

Star Equity Holdings, Inc.
Jeffrey E. Eberwein
CEO

Exhibit A:

Additional details can be found in the Certificate of Designation filed with the SEC.

Primary Logo

Source: Star Equity Holdings, Inc.

Release – Newsmax Surpasses 25 Million Social Media Followers

Posted on by [email protected]

May 6, 2026

BOCA RATON, FL / ACCESS Newswire / May 6, 2026 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced a major milestone in its digital expansion, surpassing 25 million followers across all social media platforms.

Newsmax continuous and significant growth in social media followers – up 25% from a year ago – underscores the brand’s accelerating reach and deepening engagement with audiences nationwide.

The Company reported 25.4 million total social media followers, driven by strong growth across nearly every platform.

This milestone comes alongside record-setting audience metrics, including 104.18 million in Q1 2026 Facebook user reach-a 44% increase quarter-over-quarter and an impressive 119% increase compared to the first quarter of 2025.

The Company noted that this marks the largest Facebook reach in Newsmax history.

“This growth shows that Newsmax is truly touching a nerve with audiences,” said Christopher Ruddy, CEO of Newsmax. “We are continuing to execute on our strategy to reach all people on all platforms, and the results speak for themselves.”

Newsmax’s social media expansion reflects sustained momentum across both established and emerging platforms:

  • Facebook: 6.2 million followers (+22% since June 2025)
  • YouTube Live: 2.6 million followers (+8%)
  • Truth Social: 6.9+ million followers (+61%)
  • Twitter/X: 3.7+ million followers (+7%)
  • Instagram: 2.2 million followers (+13%)
  • Gettr: 1.5 million followers (+25%)
  • TikTok: 188,000+ followers (+52%)

This widespread growth highlights Newsmax’s ability to connect with audiences across diverse demographics and content ecosystems, from traditional social giants to emerging alternative platforms.

Beyond social media, Newsmax continues to see strong performance across its broader digital footprint.

The Newsmax App has now surpassed 13 million downloads, reflecting growing demand for direct-to-consumer streaming access to the network’s programming.

The Newsmax App allows users to easily access the free Newsmax2 streaming channel, Newsmax.com, as well as the Newsmax+ paid service offering the regular Newsmax channel.

Combined with its social reach, these figures illustrate a rapidly expanding, multi-platform media presence that allows Newsmax to engage audiences wherever they consume content.

The Company attributes its growth to a combination of timely news coverage, opinion programming and a strong connection with viewers seeking fresh perspectives in the media landscape.

“Passion for our brand remains incredibly strong,” Ruddy added. “We’re seeing audiences actively seek out Newsmax across platforms, share our content and become part of a growing community that values our reporting and viewpoint.”

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 25 million combined followers. Reuters Institute has said Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

Investor Contacts

Newsmax Investor Relations
[email protected]

SOURCE: Newsmax Inc.

Release – Lion Zone Delivers Second Best Intersection Ever As Power Metallic intercepts 22.00 Meters of 11.46% CuEqRec¹ in Hole 26-095

Posted on by [email protected]

TORONTO, May 6, 2026 /CNW/ – Power Metallic Mines Inc. (the “Company” or “Power Metallic”) (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1) is pleased to provide additional assays from its winter 2026 drill program.

Lion Zone MRE In-fill program

Figure 1 – Lion Zone MRE Drill holes reported in this news release (CNW Group/Power Metallic Mines Inc.)
Figure 1 – Lion Zone MRE Drill holes reported in this news release (CNW Group/Power Metallic Mines Inc.)
Figure 2 – Location of Drill holes reported in this news release (CNW Group/Power Metallic Mines Inc.)
Figure 2 – Location of Drill holes reported in this news release (CNW Group/Power Metallic Mines Inc.)

Additional drill holes continued to add and refine the high-grade Lion Zone ahead of the 2026 Mineral Resource Estimate (MRE). The infill drill holes in this release cover approximately 560 m down plunge extent from the core of the Lion Zone (PML-26-095) to central southwestern Lion area (PML-26-069) (Figure 1). These holes highlight both the robust near surface mineralization as well as returning the deepest high-grade intercept at Lion. These holes will be incorporated into future mineral resource estimates and highlight the potential for open pit development.

Continued evolution and support of the modelled interpretation of the Lion Zone is evidenced by PML-26-095 which intersected the interpreted core of the Lion Zone with wide intersections of high-grade copper near surface with 22.00 m @ 11.46% CuEqRec1 including 6.50 m @ 18.59% CuEqRec1 and including 4.00 m @18.62% CuEqRec1 (Table 1).

Hole PML-26-069 tested the zone approximately 560 m south-southwest down plunge of PML-26-095 at a vertical depth of 600 m containing a moderate grade of 6.58 m @ 4.00% CuEqRec1 including a high-grade interval of 2.82 m @ 8.26% CuEqRec1.

Table 1: Lion Results – Winter 2026
HoleFromToLengthAuAgCuPdPtNiCuEq Rec*
(m)(m)(m)(g/t)( g/t )( %)(g/t)( g/t )( %)( %)
LION MRE 
PML-26-069674.18680.766.580.367.761.434.310.610.124.00
Including674.18677.002.820.4813.402.949.671.400.198.26
PML-26-095155.00177.0022.002.8223.374.924.795.120.2711.46
Including155.00159.004.000.6044.958.624.7618.180.4518.62
And Including160.50167.006.501.1542.889.4111.695.980.5618.59
And Including172.00175.003.0017.1211.793.412.270.040.0917.12
Note: Reported length is downhole distance; true width based on model projections is estimated as 85% of downhole length

1Copper Equivalent Rec Calculation (CuEqRec1)
CuEqRec represents CuEq calculated based on the following metal prices (USD) : 2,360.15 $/oz Au, 27.98 $/oz Ag, 1,215.00 $/oz Pd, 1000.00 $/oz Pt, 4.00 $/lb Cu, 10.00 $/lb Ni and 22.50 $/lb Co., and recovered grades based on recent locked-cycle metallurgical recoveries by SGS Canada Inc (see press release Jan 21, 2006).

Exploratory Drilling – East of Tiger

Drill holes PML-26-065, and -076, located to the east of Tiger (Figure 2), were designed to test modeled anomalies derived from the 2025 airborne VTEM survey. Both holes hit anomalous mineralization of sub-economic grades including 1 m of 0.19% Cu at 39.5-40.5 m and 1 m of 0.81 g/t Pt at 96.5-97.5m (PML-26-065). PML-25-076 displayed Lion style assemblages of Au-Cu-Ni-Pd-Pt from 207-233.5 m, averaging 0.1% CuEq. 

Power Metallic is expecting more assay results from the MRE drilling and regional exploration in the weeks to come.

“The Lion Zone continues to deliver high grade intersections that are more than an order of magnitude beyond the grade of the average producing copper mine. Hole PML-26-095 represents our second-best intersection to date. Results demonstrate that both grade and thickness are being maintained and, in places, increasing as we advance toward our inaugural Mineral Resource Estimate in the third quarter of 2026. Lots more to come!” commented Terry Lynch, CEO & Director.

Qualified Person

Joseph Campbell, P. Geo, VP Exploration at Power Metallic, is the qualified person who has reviewed and approved the technical disclosure contained in this news release.

About Power Metallic Mines Inc.

Power Metallic is a Canadian exploration company focused on advancing the Nisk Project Area (Nisk–Lion–Tiger)–a high–grade Copper–PGE, Nickel, gold and silver system–toward Canada’s next polymetallic mine.

On 1 February 2021, Power Metallic (then Chilean Metals) secured an option to earn up to 80% of the Nisk project from Critical Elements Lithium Corp. (TSX–V: CRE). Following the June 2025 purchase of 313 adjoining claims (~167 km²) from Li–FT Power, the Company now controls ~330 km² and roughly 50 km of prospective basin margins.

Power Metallic is expanding mineralization at the Nisk and Lion discovery zones, evaluating the Tiger target, and exploring the enlarged land package through successive drill programs.

Beyond the Nisk Project Area, Power Metallic indirectly has an interest in significant land packages in British Columbia and Chile, by its 50% share ownership position in Chilean Metals Inc., which were spun out from Power Metallic via a plan of arrangement on February 3, 2025.

It also owns 100% of Power Metallic Arabia which owns 100% interest in the Jabul Baudan exploration license in The Kingdon of Saudi Arabia’s Jabal Said Belt. The property encompasses over 200 square kilometres in an area recognized for its high prospectivity for copper gold and zinc mineralization. The region is known for its massive volcanic sulfide (VMS) deposits, including the world-class Jabal Sayid mine and the promising Umm and Damad deposit.

For further information, readers are encouraged to contact:
Power Metallic Mines Inc.
The Canadian Venture Building
82 Richmond St East, Suite 202
Toronto, ON

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

QAQC and Sampling

GeoVector Management Inc (“GeoVector”) is the Consulting company retained to perform the actual drilling program, which includes core logging and sampling of the drill core.

All core in this news release is either HQ or NQ sized core. Drill core is re-fitted and measured. Geotech on core includes photographs (wet & dry), rock quality index, magnetic susceptibility, conductivity, and recovery estimates. Core is logged for lithology, mineralogy, and structural features, and sample intervals are delineated and tagged.

Sampled core is mechanically sawn, and half-core is retained for future reference. GeoVector’s QAQC program includes regular insertion of CRM standards, duplicates, and blanks into the sample stream with a stringent review of all results. QAQC and data validation was performed, and no material errors were observed.

All samples were submitted to and analyzed at Activation Laboratories Ltd (“Actlabs”), a commercial laboratory independent of Power Metallic with no interest in the Project. Actlabs is an ISO 9001 and 17025 certified and accredited laboratories. Samples submitted through Actlabs are run through standard preparation methods and analysed using RX-1 (Dry, crush (< 7 kg) up to 80% passing 2 mm, riffle split (250 g) and pulverize (mild steel) to 95% passing 105 μm) preparation methods, and using 1F2 (ICP-OES) and 1C-OES – 4-Acid near total digestion + Gold-Platinum-Palladium analysis and 8-Peroxide ICP-OES, for regular and over detection limit analysis. Pegmatite samples are analyzed using UT7 – Li up to 5%, Rb up to 2% method. Actlabs also undertake their own internal coarse and pulp duplicate analysis to ensure proper sample preparation and equipment calibration.

Cautionary Note Regarding Forward-Looking Statements

This message contains certain statements that may be deemed “forward-looking statements” concerning the Company within the meaning of applicable securities laws. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “indicates,” “opportunity,” “possible” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, are subject to risks and uncertainties, and actual results or realities may differ materially from those in the forward-looking statements. Such material risks and uncertainties include, but are not limited to, among others; the timing for various drilling plans; the ability to raise sufficient capital to fund its obligations under its property agreements going forward and conduct drilling and exploration; to maintain its mineral tenures and concessions in good standing; to explore and develop its projects; changes in economic conditions or financial markets; the inherent hazards associates with mineral exploration and mining operations; future prices of nickel and other metals; changes in general economic conditions; accuracy of mineral resource and reserve estimates; the potential for new discoveries; the ability of the Company to obtain the necessary permits and consents required to explore, drill and develop the projects and if accepted, to obtain such licenses and approvals in a timely fashion relative to the Company’s plans and business objectives for the applicable project; the general ability of the Company to monetize its mineral resources; and changes in environmental and other laws or regulations that could have an impact on the Company’s operations, compliance with environmental laws and regulations, dependence on key management personnel and general competition in the mining industry.

SOURCE Power Metallic Mines Inc.

For further information on Power Metallic Mines Inc., please contact: Duncan Roy, VP Investor Relations, 416-580-3862, [email protected]

Release – Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

Posted on by [email protected]
Primary Logo

May 06, 2026 7:00am EDT

Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.)

TONMYA (cyclobenzaprine HCl sublingual tablets), the first FDA-approved treatment for fibromyalgia in adults in more than 15 years, commercially launched in November 2025

TONMYA is a first-in-class non-opioid analgesic indicated for the treatment of fibromyalgia in adults as a daily bedtime medicine for long-term use

BERKELEY HEIGHTS, N.J., May 06, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully integrated, commercial biotechnology company, today announced an agreement effective May 1, 2026, with a leading group purchasing organization (GPO) that provides coverage to approximately 35 million U.S. commercial lives, representing approximately 20% of the roughly 177 million commercial lives in the U.S., with standard utilization management criteria, for TONMYA® (cyclobenzaprine HCl sublingual tablets).

“This agreement is an important milestone in expanding patient access to TONMYA,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “We are encouraged by this first partnership with managed care and look forward to continuing to pursue additional coverage across commercial and government channels.”

Dr. Lederman continued, “TONMYA is a first-in-class non-opioid analgesic indicated for the treatment of fibromyalgia in adults. TONMYA is the first new FDA-approved treatment option for fibromyalgia in over 15 years. Fibromyalgia patients have experienced dissatisfaction with available therapies, with 85% of first-line treatments failing due to efficacy and tolerability issues.1,2 We are committed to providing patient access to TONMYA by continuing to engage with commercial payers on its value and offering a patient support program to help patients access their prescribed medication.”

Tonix also continues to progress discussions with Medicare and Medicaid. To date, TONMYA is covered under Medicaid in 38 states for approximately 55 million lives representing 73% of the roughly 75 million Medicaid lives.

The TONMYA Together Support Program offers a savings program to eligible, commercially insured patients through local pharmacies and through a digital pharmacy service. Terms and conditions apply, subject to change. Learn more at https://www.tonmya.com/savings.

About Fibromyalgia
Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts more than 10 million adults in the U.S., approximately 90% of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products.

About TONMYA® (cyclobenzaprine HCl sublingual tablets)
TONMYA (cyclobenzaprine HCl sublingual tablets) is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a multifunctional agent with potent binding and antagonist activities at the 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors, TONMYA was approved on August 15, 2025, by the FDA for the treatment of fibromyalgia in adults. TONMYA is the first new prescription medicine approved for fibromyalgia in more than 15 years. TONMYA was investigated as TNX-102 SL. TNX-102 SL is also being developed to treat acute stress disorder (ASD)/acute stress reaction (ASR), and major depressive disorder (MDD). The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10,357,465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix’s proprietary TONMYA composition. These patents are expected to provide TONMYA with U.S. market exclusivity until 2034/2035.

Citations
1Robinson RL, et al. Pain Med. 2012 13(10):1366-76. doi: 10.1111; 85% received drug treatment.
2EVERSANA primary physician research, May 2024; commissioned by Tonix.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD154/CD40 ligand (CD40L) inhibitor for the prevention of kidney transplant rejection. In addition, Tonix is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals 
[email protected]  
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
[email protected] 

Media Contacts
Deborah Elson
Tonix Pharmaceuticals
[email protected]

Ray Jordan 
Putnam Insights 
[email protected] 

INDICATION
TONMYA is indicated for the treatment of fibromyalgia in adults.

CONTRAINDICATIONS
TONMYA is contraindicated:

In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected. With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.

During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. In patients with hyperthyroidism.

WARNINGS AND PRECAUTIONS
Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.

Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.

Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.

Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.

CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities. Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS
MAO inhibitors: Life-threatening interactions may occur.

Other serotonergic drugs: Serotonin syndrome has been reported.

CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.

Tramadol: Seizure risk may be enhanced.

Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.

USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).

Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of TONMYA have not been established.

Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.

Please see additional safety information in the full Prescribing Information. To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: Tonix Pharmaceuticals Holding Corp.

Released May 6, 2026

Release – GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway

Posted on by [email protected]
GeoVax

Research News and Market Data on GOVX

Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization

ATLANTA, GA – May 6, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has initiated operational execution activities in support of its planned Phase 3 immunobridging clinical study for GEO-MVA, its Modified Vaccinia Ankara (MVA) vaccine candidate targeting mpox and smallpox.

This milestone marks GeoVax’s transition from strategic program positioning to active clinical-stage execution, following prior regulatory alignment with the European Medicines Agency (EMA) supporting an expedited development pathway.

Execution Activities Now Underway

GeoVax confirmed that multiple core execution workstreams are underway:

  • Clinical Operations: A global contract research organization (CRO) has been selected
  • Trial Infrastructure Activation: Clinical site identification and activation planning progressing in alignment with study requirements
  • Manufacturing Readiness: Clinical trial material manufactured and fill/finish product has been completed and released for clinical use
  • Regulatory Execution Alignment: Ongoing implementation of EMA-guided immunobridging strategy designed to support an efficient path to authorization

The planned Phase 3 immunobridging arm of the clinical trial is expected to enroll approximately 500 participants and evaluate neutralizing antibody responses relative to the approved MVA-based comparator vaccine. This study design intentionally provides rapid clinical validation, further de-risking the program in addition to the expedited development pathway.

From Defined Pathway to Active Execution

“We are now executing against a clearly defined clinical and regulatory pathway for GEO-MVA,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “Our focus has shifted decisively to operational execution of the Phase 3 program. The EMA’s guidance provides a structured and efficient pathway centered on immunobridging, and we are advancing accordingly.”

Dodd added, “Our objective is to move efficiently through study initiation and execution, positioning GEO-MVA to support global preparedness needs while advancing toward potential regulatory authorization.  Our study plan is structured to provide the immunobridging study results within 8-12 weeks following trial initiation.”

Positioned for Efficient Clinical Advancement

The EMA-supported immunobridging approach is designed to:

  • Leverage established MVA platform experience
  • Focus on quantitative neutralizing antibody endpoints
  • Enable a streamlined development pathway relative to traditional efficacy trials

GeoVax believes this approach supports a clear and actionable pathway from development toward potential commercialization.

Addressing a Critical Global Need

GEO-MVA is being advanced as a potential second-source MVA-based vaccine, addressing ongoing global demand for orthopoxvirus vaccines and reducing reliance on a single supplier.

Public health agencies and governments continue to emphasize the importance of resilient and diversified vaccine supply, particularly in the context of evolving mpox dynamics and preparedness requirements.

About GEO-MVA

GEO-MVA is GeoVax’s candidate vaccine for protection against mpox and smallpox based on the Modified Vaccinia Ankara (MVA). The program is advancing under an expedited regulatory pathway supported by EMA scientific advice, which enables potential regulatory approval based on a single immune bridging study demonstrating non-inferiority to an approved MVA vaccine.

Following successful completion of the planned study, GEO-MVA is expected to advance toward regulatory submission and potential commercialization as an additional source of MVA vaccine supply for global preparedness and biodefense programs.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected] 

The Numbers Don’t Lie: Small Caps Are Outrunning the S&P 500 — and the Institutional Money Is Finally Catching Up

Posted on by [email protected]

For years, the story of the U.S. equity market was written by a handful of mega-cap technology names. That story is being rewritten in 2026, and small-cap investors are the ones holding the pen.

The Russell 2000 is up approximately 12% year-to-date, more than double the S&P 500’s roughly 5% gain over the same period. That gap isn’t noise — it reflects a meaningful structural shift in where capital is flowing and why.

The earnings picture is the starting point. Small-cap companies are projected to deliver 18% to 22% earnings growth for the full year in 2026, compared to roughly 13% for large caps. Analyst forecasts extend that outperformance into 2027 as well, with another 17–18% growth expected — suggesting this isn’t a one-quarter anomaly but the early stage of a sustained cycle.

The valuation argument reinforces the case. The S&P 500 currently trades near 28 times earnings. The Russell 2000 trades around 18 times. The S&P 600 — widely considered the higher-quality small-cap benchmark — sits near 16 times forward earnings. That’s a discount of roughly 40% to large caps. Historically, gaps of that magnitude don’t persist; they close, and when they do, small-cap investors collect outsized returns.

The macro setup has been equally supportive. The Federal Reserve’s rate-cutting cycle throughout 2025, which brought the federal funds rate to the 3.50%–3.75% range, disproportionately benefited smaller companies that carry more floating-rate debt. As interest expense declined, margins expanded — and earnings started to catch up to valuations.

M&A activity is amplifying the opportunity. U.S. transaction volume for deals over $100 million is up 25% by deal count and 43% by value in early 2026, with private equity firms deploying capital after years of sitting on record dry powder. For small-cap shareholders, that dealmaking environment creates a meaningful premium opportunity — acquisitions of quality small-cap targets at 30–40% premiums are not uncommon in the current environment.

Domestic revenue exposure is adding another layer of appeal. In an environment where tariff uncertainty and global supply chain risk remain real considerations, companies with predominantly U.S.-focused revenue streams are commanding renewed investor attention. Many small and microcap companies fit that profile by nature.

None of this means every small-cap stock is a buy. The rotation is rewarding companies with strong balance sheets, reliable cash flow, and a defensible market position. Those carrying excessive debt or lacking a clear path to profitability are being bypassed. The quality filter is real.

But for investors who track the small and microcap space — the roughly $250 million to $2 billion market cap range where institutional coverage is thin and price discovery is still happening — the current setup represents one of the more compelling opportunities in recent memory. The window doesn’t stay open indefinitely.

Ocugen (OCGN) – 1Q26 Reported With Senior Convertible Note Offering

Posted on by [email protected]


Wednesday, May 06, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Clinical Progress During 1Q26 Reviewed. Ocugen reported 1Q26 loss of $19.1 million or $(0.06) per share, slightly higher than we estimated. On its quarterly conference call, management reiterated several important clinical milestones in the coming year. The company also completed an offering of $115 million in Convertible Senior Notes, which we estimate is enough cash to bring its three lead products to market and fund operations through early 2028. The proposal to allow for a reverse split has been dropped from the Annual Meeting agenda.

Senior Note Offering Provides Sufficient Cash For Product Introductions. The cash balance on March 31, 2026, was $32.2 million, including proceeds of $37.5 million from warrant exercise in 1Q26. Today, the company completed the sale of $115 million in 6.75% Convertible Senior Notes. including an option for the buyer to purchase an additional $15 million in the next 13 days. These Notes should add about $99.5 million to the cash balance. Based on our estimates, we believe this is sufficient to fund operations through the filing of the BLAs and product introductions expected in 2026-2028.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SelectQuote (SLQT) – Strong Q3 Execution Highlights Profitability and Cash Flow Strength

Posted on by [email protected]


Wednesday, May 06, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Q3 Adj EBITDA. The company reported fiscal Q3 revenue of $430.9 million and adj. EBITDA of $44.6M. While revenue was modestly lower than our estimate of $449.0M, adj. EBITDA strongly outperformed our estimate of $35.0M. Notably, adj. EBITDA benefited from a favorable $14.0M adjustment to commissions receivables and continued operational discipline.

Underlying profitability remains solid. Normalized EBITDA margins were approximately 7% after excluding the one-time commission benefit. Core operating performance appears to be improving. The Senior segment demonstrated resilience despite ongoing headwinds in Medicare Advantage. Healthcare Services (SelectRx) revenue grew 5% YoY to $199M, driven by continued membership growth and higher prescription utilization per member.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FreightCar America (RAIL) – First Quarter 2026 Review and Outlook

Posted on by [email protected]


Wednesday, May 06, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1′ 2026 financial results. RAIL generated a Q1′ 2026 adjusted net loss of $479 thousand or $(0.04) per share, compared to adjusted net income of $1.6 million or $0.05 per share in Q1′ 2025. We had projected net income of $550 thousand or $0.02 per share. Revenue declined to $64.3 million compared to $96.3 million during the prior year period, while railcar deliveries fell to 577 compared to 710 units in the prior year period and our estimate of 700 units. Adjusted EBITDA declined to $3.2 million compared to $6.4 million in Q1′ 2025 and our estimate of $5.8 million.

FY 2026 guidance maintained. Management reiterated its FY 2026 guidance. Railcar deliveries are expected to be in the range of 4,000 to 4,500, revenue in the range of $500 to $550 million, and adjusted EBITDA of $41 to $50 million. Based on management’s commentary during the investor call, we believe the 2026 guidance is achievable.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.